Through bioactivity screening and molecular docking, the investigators identified L61H46, a small molecule targeting STAT3 signaling in vitro and in vivo, which effectively reduced pancreatic cancer cell viability, significantly inhibited STAT3 phosphorylation and subsequent nuclear translocation, and showed no adverse effects on the liver, heart, and kidney cells in a xenograft tumor model [80]. This evidence concerns the gene STAT3 and neoplasm.